CAAR-Ts represent a targeted approach to therapy of antibody-mediated autoimmune diseases, with the potential for generation of long-term memory CAAR-Ts that can potentially cure disease. Autoantigen-based chimeric immunoreceptors (CAAR) can direct T cells to kill autoreactive B lymphocytes through the specificity of the B cell receptor (BCR). The vector of anti-MUC1 chimeric autoantigen receptor (CAAR) is constructed for the engineering of T cells to target Human MUC1. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-MUC1 antibody linked to lung-cancer.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE